Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
Recruiting in Palo Alto (17 mi)
+156 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: GlaxoSmithKline
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.
Eligibility Criteria
Inclusion Criteria
Written informed consent (patient's written understanding of and agreement to participate in this study).
Patients with confirmed extensive small cell lung cancer (SCLC).
No prior chemotherapy within 5 years of the diagnosis of SCLC.
See 4 more
Treatment Details
Interventions
- FDA Approved Chemotherapy (Chemotherapy)
- Investigational Drug (Investigational Drug)
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
GSK Clinical Trials Call CenterChicago, IL
GSK Clinical Trials Call CenterFrederick, MD
GSK Clinical Trials Call CenterSt. Louis, MO
GSK Clinical Trials Call CenterSpartanburg, SC
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
GlaxoSmithKlineLead Sponsor